ARTICLE | Company News
Genelabs, Gilead deal
October 4, 2004 7:00 AM UTC
The companies partnered to identify and develop nucleoside inhibitors of HCV polymerase. GNLB will lead the research, and GILD will focus on development and commercialization. GNLB will receive an $8 ...